Quick Answer
Pasithea Therapeutics Corp. reported Research And Development Expense of $7.98 million for the year ending 2025.
- Pasithea Therapeutics Corp. showed an increase of +10.9% in Research And Development Expense from 2024 to 2025.
- This data is from Pasithea Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $1.28 million | Q1 2023: $1.10 million | Q2 2023: $2.03 million | Q3 2023: $1.62 million | Q1 2024: $1.75 million | Q2 2024: $2.36 million | Q3 2024: $1.58 million | Q1 2025: $1.73 million | Q2 2025: $2.15 million | Q3 2025: $1.36 million.
- Over the full 4 years of available data (2022 to 2025), Pasithea Therapeutics Corp.'s Research And Development Expense has grown by 199.4%.
- Historical annual values: Fiscal year 2025: $7.98 million | Fiscal year 2024: $7.20 million | Fiscal year 2023: $8.10 million | Fiscal year 2022: $2.67 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: